VivoSeq
Other

White Spot Lesions

0

Pipeline Programs

6

Active Trials

1

Companies Involved

White Spot Lesions is an early-stage landscape with 0 programs across 1 company. The most active players are Sigmund Freud PrivatUniversitat.

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

89/100

Attrition Rate

4/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

27

clinical trials

Unknown status12 · 44%
Completed8 · 30%
Recruiting3 · 11%
Not yet recruiting2 · 7%
Withdrawn1 · 4%
Active, not recruiting1 · 4%

Trial Activity

27 trials

Bioactive Glass in the Treatment of Enamel White Spot Lesions
Completed··Phase 3·NCT04401280·60 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)